Dr. Lal PathLabs has successfully completed its bonus share allotment, with the Board of Directors approving the issuance through a circular resolution on December 22, 2025. The company allotted 8,37,75,510 fully paid-up bonus equity shares in the ratio of 1:1 to eligible shareholders.

Bonus Share Allotment Details

The bonus shares were allotted to shareholders whose names appeared in the Register of Members or List of Beneficial Owners as of the record date of December 19, 2025. Each eligible shareholder received one new fully paid-up equity share for every existing share held.

Enhanced Capital Structure

Following the bonus share allotment, the company's paid-up equity share capital has doubled from ₹83.78 crores to ₹167.55 crores. The total number of outstanding shares increased from 8.38 crores to 16.76 crores.

Previous Corporate Actions

Prior to this allotment, the company had announced a second interim dividend of ₹7.00 per equity share for the financial year 2025-26, with a record date of November 7, 2025. The company had also paid an earlier interim dividend of ₹6.00 per share in August 2025.

The bonus shares allotted rank pari-passu in all respects with the existing fully paid-up equity shares of the company. The allotment was funded from the company's Securities Premium Account, which stood at ₹1,247.85 million as per the audited financial statements for the year ended March 31, 2025.

Dr. Lal Path Labs , a leading diagnostic and healthcare service provider, has reported strong financial results for the second quarter, along with an announcement of a bonus share issue.

Q2 Financial Highlights

Dr. Lal PathLabs has demonstrated robust growth in its Q2 performance:

The company maintained a healthy EBITDA margin of 30.7%, showcasing its operational efficiency.

Bonus Share Announcement

The Board of Directors has approved a bonus share issue in the ratio of 1:1. This means shareholders will receive one new fully paid-up equity share for every existing share held.

Key details of the bonus issue include:

• Ratio: 1:1 (One bonus share for each existing share)
• Face Value: INR 10 per share
• Eligibility: Shareholders as of the yet-to-be-announced record date
• Issuance: Subject to shareholder and regulatory approvals

Additional Corporate Actions

The company has also declared other significant corporate actions:

1. Interim Dividend: A second interim dividend of INR 7 per equity share (70% on face value of INR 10) for the financial year 2025-26.

2. Increase in Authorized Share Capital: The company plans to increase its authorized share capital from INR 1,07,96,00,000 to INR 2,00,00,00,000, subject to shareholder approval.

3. Employee Stock Option Plan: Introduction of "Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025" (RSU 2025), allocating options from the existing Employee Stock Option Plan 2022.

Market Implications

The combination of strong financial performance and shareholder-friendly actions like the bonus issue may potentially boost investor confidence in Dr. Lal PathLabs. The bonus issue could increase the liquidity of the stock without affecting the company's valuation.

As the healthcare sector continues to be a focus area for investors, Dr. Lal PathLabs' performance and strategic decisions may be closely watched by market participants for indications of broader sector trends.

Investors and shareholders should note that the record date for the bonus issue and other corporate actions will be announced in due course, and all actions are subject to necessary approvals.